Trial Outcomes & Findings for Transcranial Direct Current Stimulation for Primary Progressive Aphasia (NCT NCT02928848)
NCT ID: NCT02928848
Last Updated: 2021-06-03
Results Overview
The Western Aphasia Battery (WAB) was administered at baseline and immediately post-tDCS (real; sham) following the termination of the tDCS session on the same day (0 week). We computed WAB-Aphasia Quotient (WAB-AQ), a measure of overall aphasia severity with higher scores indicating better language performance. The WAB assesses the following language domains in subtests: fluency, comprehension, repetition, and naming. We examined change in WAB-AQ and each of the sub-tests from baseline. Difference scores were computed by subtracting the post-intervention score (0 weeks) from baseline for each study arm to assess the impact of real/active vs sham tDCS on severity and each sub-test. Scale title: WAB-AQ; scale values: 0-100; higher scores=better outcome.
COMPLETED
NA
16 participants
Difference in WAB-AQ from Baseline at 0-weeks Post-stimulation
2021-06-03
Participant Flow
Recruitment period: 10/2017-11/2019. Patients with Primary Progressive Aphasia will be recruited from the clinical practices of Drs. H. Branch Coslett, Roy Hamilton, and Murray Grossman at the Hospital of the University of Pennsylvania. Additional recruitment measures involve flyers posted around the University of Pennsylvania campus and the Hospital of the University of Pennsylvania grounds, as well as online FTD/PPA support groups and in-person support groups around the Philadelphia area.
16 participants were enrolled in the study. Subjects were enrolled if they were native English speakers, right handed, and received a diagnosis of primary progressive aphasia (PPA). Note that one participant was diagnosed as having PPA at the time of enrollment; however, it was later learned that this was a misdiagnosis and their data were not analyzed. Baseline Characteristics reported for N=13. The washout period between treatment arms was 12 weeks.
Participant milestones
| Measure |
Active tDCS, Then Sham tDCS
Transcranial direct current stimulation (tDCS) is a type of noninvasive brain stimulation that modulates the resting excitability of neuronal populations, thereby altering patterns of brain activity in potentially behaviorally relevant ways. The active stimulation involves 20 minutes of constant stimulation at 1.5 mA intensity. Following a washout period of 12 weeks after active tDCS in Arm 1, subjects then crossed over to treatment Arm 2, and received sham tDCS.
|
Sham tDCS, Then Active tDCS
Sham tDCS uses identical stimulation parameters as the active condition, however terminates after 30 seconds in order to mimic the sensation of active tDCS. Following a washout period of 12 weeks after sham tDCS in Arm 1, subjects then crossed over to treatment Arm 2, and received active tDCS.
|
|---|---|---|
|
Arm 1
STARTED
|
9
|
7
|
|
Arm 1
COMPLETED
|
9
|
6
|
|
Arm 1
NOT COMPLETED
|
0
|
1
|
|
Arm 2
STARTED
|
9
|
6
|
|
Arm 2
COMPLETED
|
8
|
6
|
|
Arm 2
NOT COMPLETED
|
1
|
0
|
Reasons for withdrawal
| Measure |
Active tDCS, Then Sham tDCS
Transcranial direct current stimulation (tDCS) is a type of noninvasive brain stimulation that modulates the resting excitability of neuronal populations, thereby altering patterns of brain activity in potentially behaviorally relevant ways. The active stimulation involves 20 minutes of constant stimulation at 1.5 mA intensity. Following a washout period of 12 weeks after active tDCS in Arm 1, subjects then crossed over to treatment Arm 2, and received sham tDCS.
|
Sham tDCS, Then Active tDCS
Sham tDCS uses identical stimulation parameters as the active condition, however terminates after 30 seconds in order to mimic the sensation of active tDCS. Following a washout period of 12 weeks after sham tDCS in Arm 1, subjects then crossed over to treatment Arm 2, and received active tDCS.
|
|---|---|---|
|
Arm 2
Withdrawal by Subject
|
1
|
0
|
Baseline Characteristics
Transcranial Direct Current Stimulation for Primary Progressive Aphasia
Baseline characteristics by cohort
| Measure |
Active tDCS, Then Sham
n=7 Participants
Transcranial direct current stimulation (tDCS) is a type of noninvasive brain stimulation that modulates the resting excitability of neuronal populations, thereby altering patterns of brain activity in potentially behaviorally relevant ways. The active stimulation condition involves 20 minutes of constant stimulation at 1.5 mA. Arm 1 data were collected prior to active tDCS, whereas Arm 2 data reflect performance 12 weeks following active tDCS (prior to crossing over to the sham tDCS treatment arm).
|
Sham tDCS, Then Active
n=6 Participants
Sham tDCS uses identical stimulation parameters as the active condition, however terminates after 30 seconds in order to mimic the sensation of real tDCS. Arm 1 data were collected prior to sham tDCS, whereas Arm 2 data reflect performance 12 weeks following sham tDCS (prior to crossing over to the active tDCS treatment arm).
|
Total
n=13 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
3 Participants
n=5 Participants
|
2 Participants
n=7 Participants
|
5 Participants
n=5 Participants
|
|
Age, Categorical
>=65 years
|
4 Participants
n=5 Participants
|
4 Participants
n=7 Participants
|
8 Participants
n=5 Participants
|
|
Age, Continuous
|
66.29 years
STANDARD_DEVIATION 7.67 • n=5 Participants
|
66.33 years
STANDARD_DEVIATION 6.18 • n=7 Participants
|
66.31 years
STANDARD_DEVIATION 6.73 • n=5 Participants
|
|
Sex: Female, Male
Female
|
3 Participants
n=5 Participants
|
2 Participants
n=7 Participants
|
5 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
4 Participants
n=5 Participants
|
4 Participants
n=7 Participants
|
8 Participants
n=5 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=5 Participants
|
2 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
White
|
7 Participants
n=5 Participants
|
4 Participants
n=7 Participants
|
11 Participants
n=5 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Region of Enrollment
United States
|
7 participants
n=5 Participants
|
6 participants
n=7 Participants
|
13 participants
n=5 Participants
|
|
Western Aphasia Battery - Aphasia Quotient (WAB-AQ)
Arm 1
|
79.84 units on a scale
STANDARD_DEVIATION 9.68 • n=5 Participants
|
85.55 units on a scale
STANDARD_DEVIATION 7.80 • n=7 Participants
|
82.38 units on a scale
STANDARD_DEVIATION 9.61 • n=5 Participants
|
|
Western Aphasia Battery - Aphasia Quotient (WAB-AQ)
Arm 2
|
78.39 units on a scale
STANDARD_DEVIATION 9.24 • n=5 Participants
|
85.55 units on a scale
STANDARD_DEVIATION 7.02 • n=7 Participants
|
81.23 units on a scale
STANDARD_DEVIATION 10.10 • n=5 Participants
|
PRIMARY outcome
Timeframe: Difference in WAB-AQ from Baseline at 0-weeks Post-stimulationPopulation: Participants who completed both arms of the study to the 0-week follow-up (N=13). Of the 16 participants enrolled, 3 were excluded from the 0-week follow-up for the following reasons: withdrew prior to starting treatment arm 1 (n=2) and misdiagnosed as PPA (n=1).
The Western Aphasia Battery (WAB) was administered at baseline and immediately post-tDCS (real; sham) following the termination of the tDCS session on the same day (0 week). We computed WAB-Aphasia Quotient (WAB-AQ), a measure of overall aphasia severity with higher scores indicating better language performance. The WAB assesses the following language domains in subtests: fluency, comprehension, repetition, and naming. We examined change in WAB-AQ and each of the sub-tests from baseline. Difference scores were computed by subtracting the post-intervention score (0 weeks) from baseline for each study arm to assess the impact of real/active vs sham tDCS on severity and each sub-test. Scale title: WAB-AQ; scale values: 0-100; higher scores=better outcome.
Outcome measures
| Measure |
Active tDCS, Then Sham tDCS
n=7 Participants
Transcranial direct current stimulation (tDCS) is a type of noninvasive brain stimulation that modulates the resting excitability of neuronal populations, thereby altering patterns of brain activity in potentially behaviorally relevant ways. The active stimulation involves 20 minutes of constant stimulation at 1.5 mA intensity. Following a washout period of 12 weeks after active tDCS in Arm 1, subjects then crossed over to treatment Arm 2, and received sham tDCS.
|
Sham tDCS, Then Active tDCS
n=6 Participants
Sham tDCS uses identical stimulation parameters as the active condition, however terminates after 30 seconds in order to mimic the sensation of active tDCS. Following a washout period of 12 weeks after sham tDCS in Arm 1, subjects then crossed over to treatment Arm 2, and received active tDCS.
|
|---|---|---|
|
Aphasia Severity (WAB-AQ): Effects of Active tDCS (Baseline vs. 0 Weeks Immediately Following Stimulation)
Arm 1: 0 Week Follow-up
|
2.68 score on a scale
Standard Deviation 2.04
|
.87 score on a scale
Standard Deviation 2.83
|
|
Aphasia Severity (WAB-AQ): Effects of Active tDCS (Baseline vs. 0 Weeks Immediately Following Stimulation)
Arm 2: 0 Week Follow-up
|
1.98 score on a scale
Standard Deviation 2.75
|
2.25 score on a scale
Standard Deviation 2.04
|
SECONDARY outcome
Timeframe: Difference in WAB Naming Subtest from Baseline at 0-weeks Post-stimulationPopulation: Participants who completed both arms of the study to the 0-week follow-up (N=13). Of the 16 participants enrolled, 3 were excluded from the 0-week follow-up for the following reasons: withdrew prior to starting treatment arm 1 (n=2) and misdiagnosed as PPA (n=1).
WAB-naming subtest used common objects as stimuli. Participants were required to name the objects. Three-point maximum score could be earned for each stimulus and a total of 60-points could be earned on this task; points were deducted if the response was incorrect and required a cue or if the response included a paraphasia.
Outcome measures
| Measure |
Active tDCS, Then Sham tDCS
n=7 Participants
Transcranial direct current stimulation (tDCS) is a type of noninvasive brain stimulation that modulates the resting excitability of neuronal populations, thereby altering patterns of brain activity in potentially behaviorally relevant ways. The active stimulation involves 20 minutes of constant stimulation at 1.5 mA intensity. Following a washout period of 12 weeks after active tDCS in Arm 1, subjects then crossed over to treatment Arm 2, and received sham tDCS.
|
Sham tDCS, Then Active tDCS
n=6 Participants
Sham tDCS uses identical stimulation parameters as the active condition, however terminates after 30 seconds in order to mimic the sensation of active tDCS. Following a washout period of 12 weeks after sham tDCS in Arm 1, subjects then crossed over to treatment Arm 2, and received active tDCS.
|
|---|---|---|
|
Naming Ability (WAB Naming Subtest): Effects of Active tDCS Baseline vs. 0 Weeks Immediately Following Stimulation
Arm 1: 0-week Follow-up
|
.63 score on a scale
Standard Deviation .49
|
.11 score on a scale
Standard Deviation .59
|
|
Naming Ability (WAB Naming Subtest): Effects of Active tDCS Baseline vs. 0 Weeks Immediately Following Stimulation
Arm 2: 0-week Follow-up
|
.26 score on a scale
Standard Deviation .83
|
.63 score on a scale
Standard Deviation .35
|
Adverse Events
Active tDCS
Sham tDCS
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place